Results for all evidence | Drugs and Technologies | Prescribing and Technical Information | NHS England 1 - 7 of 7 sorted by relevance / date

Click export CSV or RIS to download the entire page or use the checkboxes to select a subset of records to download

Atlas of variation in NHS Diagnostic services in England 2017

Source: Public Health England - PHE - Remove: NHS England source - 01 May 2017 - Publisher: NHS England;Public Health England

The data and information presented in each of the atlases do not always explain the reason for the variation, however the strength and power of the atlas series is in the questions they raise about...

Read Summary

- Remove: Prescribing and Technical Information filter
Branded Health Service Medicines (Costs) Regulations 2018: annual review for 2019 [PDF]

Remove: Department of Health source - 29 March 2019 - Publisher: Department of Health

This is the first annual review of the regulations relating to the statutory scheme for branded medicines pricing, which came into force on 1 April 2018.

Read Summary

- Remove: Prescribing and Technical Information filter
Antigen-specific active immunotherapy for ovarian cancer

Remove: NICE Quality and Productivity Case Studies source - 17 November 2014 - Publisher: Queen's University Belfast

NICE summary of review conclusions Antigen-specific active immunotherapy for ovarian cancer is not supported by sufficient good quality evidence. Consideration could be given to using it only...

Read Summary

- More: Case Studies

- Remove: Quality Indicators filter
Blocks: Tools and methodologies to assess integrated care in Europe [PDF]

Remove: European Commission source - 01 March 2017 - Publisher: European Commission

Measuring integration is different from measuring the performance of integrated care. This report addresses this dual challenge: on the one hand it focuses on design principles, building...

Read Summary

- More: Primary Research

- More: Evidence Summaries

- Remove: Quality Indicators filter
Innovation scorecard: use of medical technologies per 100,000 resident population October 2014 to September 2015

Remove: NHS England source - 01 May 2016 - Publisher: NHS England

May 2016 heat maps - Medical technologies at CCG level. The information is presented in a heat map to provide a graphical representation of the data on medicines. Data can be used to compare...

Read Summary

- Remove: Prescribing and Technical Information filter
Rescheduling of Gabapentin and Pregabalin as Schedule 3 Controlled Drugs

Remove: NHS England source - 11 March 2019 - Publisher: NHS England

This guidance document provides information on changes to the law relating to the reclassification of the drugs pregabalin and gabapentin.

SPS comment

- Remove: Prescribing and Technical Information filter
National Dose Banding Table – Durvalumab 50mg/ml

Remove: NHS England source - 21 June 2019 - Publisher: NHS England

This national dose banding table is to be used by hospital trust pharmacy teams to ensure a standard approach to dose banding of chemotherapy across all hospital trusts. The table is intended to be...

Read Summary

- Remove: Prescribing and Technical Information filter

Filter results by

Results for all evidence | Drugs and Technologies | Prescribing and Technical Information | NHS England 1 - 7 of 7 sorted by relevance / date

Atlas of variation in NHS Diagnostic services in England 2017

Branded Health Service Medicines (Costs) Regulations 2018: annual review for 2019 [PDF]

Antigen-specific active immunotherapy for ovarian cancer

Blocks: Tools and methodologies to assess integrated care in Europe [PDF]

Innovation scorecard: use of medical technologies per 100,000 resident population October 2014 to September 2015

Rescheduling of Gabapentin and Pregabalin as Schedule 3 Controlled Drugs

National Dose Banding Table – Durvalumab 50mg/ml